Expert Interview
Discussing novel therapeutics to treat gastric cancer/GEJ Adenocarcinoma, including Leap Therapeutics' DKN-01 (anti-DKK1) on top of PD-1 and chemo, as well as Claudin 18.2 (Zolbetuximab from Astellas, & SYSA1801 from Elevation Oncology)
Ticker(s): LPTX, ELEV, ALPMYInstitution: Mayo Clinic
- Board certified in Internal medicine, Hematology, and Oncology
- Specializes in gastrointestinal (GI) malignancies and treats conditions such as: neuroendocrine tumors (NETs); neuroendocrine carcinoma (NEC); colon cancer; esophageal cancer; liver cancer; pancreatic cancer, and stomach cancer; and has co-authored papers and book chapters on these subjects.
- Clinical research interest and expertise in neuroendocrine tumors, for which he currently treats ~200 patients with NETS.
How do you currently treat gastric cancer?
Added By: wilson_adminWhat are your impressions of the data shown from DKN-01?
Added By: wilson_adminWhat are your impressions of the data shown from the anti Claudin 18.2 therapies?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
